People with major depressive disorder who have not responded to standard treatments now have a new option they can use from their own homes. The FDA granted Premarket Approval to the Flow FL-100, a headset that delivers transcranial direct current stimulation (tDCS) through a paired app, making it the first at-home brain-stimulation device to clear the agency’s most rigorous review pathway for treating severe depression. The approval, filed under PMA number P230024, shifts a therapy that has historically required repeated clinic visits into a self-administered format, raising immediate questions about access, oversight, and insurance coverage.
Why an at-home brain-stimulation device changes the treatment equation
Until now, noninvasive brain stimulation for depression has largely meant in-office sessions of repetitive transcranial magnetic stimulation (TMS), a treatment that typically requires weeks of daily appointments at a specialized clinic. The National Institute of Mental Health includes TMS among its established brain stimulation options for mood disorders, but access depends heavily on geography. Rural areas and smaller metro regions often lack TMS providers entirely, forcing patients to travel long distances, relocate temporarily, or forgo the treatment.
The Flow FL-100 sidesteps that bottleneck. By allowing patients to self-administer tDCS sessions at home under a physician’s prescription, the device could reach people in areas where clinic-based neuromodulation simply does not exist. That geographic mismatch is the most likely early driver of adoption. Within the next 18 months, state-level prescription or claims data should reveal whether uptake of the Flow FL-100 tracks more closely with regional shortages of TMS clinics than with published differences in efficacy between tDCS and TMS. If it does, the device’s real-world value will be less about outperforming existing treatments and more about filling gaps where no treatment was practically available.
The distinction between “approved” and “cleared” matters here. The FDA reserves Premarket Approval for higher-risk devices that require clinical evidence of safety and effectiveness, a stricter standard than the 510(k) clearance process used for devices that are substantially equivalent to something already on the market. The agency’s own device-approval materials draw a sharp line between these pathways. That the Flow FL-100 went through PMA, documented in the agency’s public record, signals the FDA required a full clinical dataset before greenlighting home use.
What the clinical trial showed about home-delivered tDCS
The core evidence behind the approval comes from a fully remote phase 2 randomized sham-controlled trial published in Nature Medicine. The study tested a home-based tDCS protocol for major depressive disorder, using the headset-plus-app workflow that the commercial device now replicates. Participants received either active stimulation or a sham version, and the entire trial was conducted without in-person clinic visits, a design choice that directly tested whether remote delivery could work. The peer-reviewed article describing this protocol and its outcomes is available in the Nature Medicine report.
The trial’s publication provides the strongest publicly available evidence for the device’s effectiveness. The FDA’s PMA summary confirms the regulatory action but does not, at this stage, include the full endpoint statistics or detailed adverse-event tables from the sponsor’s submission. That leaves the Nature Medicine paper as the primary window into what the device does in controlled conditions, including how depressive symptoms changed over time and how sham and active arms compared.
The trial’s remote design is itself a statement about the intended use case. Traditional TMS trials require patients to come into a clinic for every session, which introduces selection bias toward people who live near providers, have flexible schedules, and can afford transportation. By running the study entirely at home, the researchers tested not just whether tDCS reduces depressive symptoms but whether patients can safely and reliably self-administer it without direct clinical supervision during each session. Adherence, correct placement of electrodes, and accurate reporting of side effects all had to be managed through the app and remote monitoring rather than face-to-face visits.
In practical terms, the study suggests that a subset of adults with major depressive disorder can follow a structured home-stimulation schedule and experience clinically meaningful symptom improvements compared with a sham condition. However, the participants were still a selected research population, screened for inclusion and exclusion criteria, and supported by a trial infrastructure that may not be identical to routine clinical use.
Gaps in the evidence and what patients should watch for
Several questions remain open. The published trial is a phase 2 study, designed primarily to assess efficacy signals and safety in a controlled population, not to measure long-term outcomes across diverse real-world users. No phase 3 data or post-market surveillance results specific to the Flow FL-100 are publicly available in FDA documents reviewed for this article. Long-term safety data, including whether repeated home use produces different adverse-event profiles than clinic-administered brain stimulation, has not been reported in any institutional source cited here.
Another uncertainty is durability of benefit. The Nature Medicine trial followed participants for a limited period, sufficient to detect short-term changes in depressive symptoms but not to answer how long improvements last, how often maintenance sessions might be needed, or what happens when patients stop and restart treatment. For people weighing an at-home device, these are practical questions that may only be answered once larger, longer studies or registry data become available.
Insurance coverage is also unresolved. Existing Medicare policies for neuromodulation, such as local coverage determinations for TMS, outline evidence requirements and FDA history for clinic-based treatments but do not address at-home tDCS or the Flow FL-100 specifically. Without a clear billing pathway or coverage decision, patients prescribed the device may face substantial out-of-pocket costs, potentially limiting the very access gains the technology promises. Private insurers have not, in publicly accessible policy documents, announced definitive positions on reimbursement.
Clinicians will have to navigate these gaps in parallel with emerging real-world experience. For some patients-particularly those far from TMS centers or those who have exhausted medication options-the possibility of home-based brain stimulation may justify trying a newer modality with incomplete long-term data. For others, especially individuals with complex psychiatric or medical comorbidities, the lack of extensive safety and durability evidence may argue for continuing with more established, closely monitored treatments where available.
How clinicians and patients might integrate the Flow FL-100
For now, the Flow FL-100 is best understood as an additional tool in the treatment-resistant depression toolbox rather than a replacement for medications, psychotherapy, or in-clinic neuromodulation. Its most immediate role is likely as an option for adults who have not responded to standard antidepressants and who either cannot access or do not wish to pursue clinic-based TMS or electroconvulsive therapy.
Prescribing clinicians will need to assess a patient’s ability to manage a home device safely: following instructions, recognizing and reporting side effects, and maintaining consistent use over weeks. The remote trial suggests that with appropriate digital support, many patients can do this, but real-world adherence outside a research context remains to be seen.
Patients considering the device can ask a few practical questions during consultation: how its expected benefits compare with other available treatments; what is known-and not yet known-about long-term safety; how costs will be handled if insurance does not cover the device; and what kind of follow-up monitoring the prescriber will provide. Because the PMA pathway requires evidence of both safety and effectiveness, the device has cleared a higher regulatory bar than many consumer wellness gadgets, but that does not eliminate the need for ongoing clinical judgment.
As prescriptions begin and insurers, regulators, and researchers watch outcomes, the Flow FL-100 will serve as an early test case for whether complex brain-stimulation therapies can move safely from the clinic into the home. The answers will shape not only the future of tDCS for depression but also how far regulators and clinicians are willing to go in decentralizing advanced psychiatric care.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
